Eupraxia reaches 120 — patient enrollment target in Phase 2b trial of EP — 104GI for eosinophilic esophagitis
Eupraxia Pharmaceuticals reached its 120-patient enrollment target for the Phase 2b RESOLVE trial of EP-104GI for eosinophilic esophagitis on October 12, 2026. Interim results are expected in December 2026, covering symptoms, tissue findings and safety. Safety observations to date indicate EP-104GI has been generally w